Lauren M. Brown

The paper introduces a probe-based workflow to detect oncogenic gene fusions in single-cell RNA-seq, validated in cancer cell lines and pediatric B-ALL cohorts.

This paper introduces CRISPR-PspCas13b as a method to systematically silence oncogenic fusion transcripts, showing effectiveness against drug-resistant cancer drivers.

TALLSorts classifies T-ALL samples using bulk RNA-seq data with high accuracy across four international cohorts.

Toblerone detects exon deletions in RNA-seq data, specifically applied to IKZF1 in B-ALL samples, identifying deletions associated with poor prognosis.

This study designs CRISPR-Cas13b crRNAs with single-base precision to silence oncogenic gene fusions, enhancing targeting efficacy and selectivity.

ALLSorts classifies B-ALL samples into 18 subtypes and five meta-subtypes using RNA-Seq data with high accuracy.